Turn this list into pipeline.
Pharmaceuticals Companies in Swansea: 32 Active Firms (2026)
Pharmaceuticals companies in Swansea develop, manufacture or distribute medicines under MHRA-regulated quality and safety requirements.
Buying centres in Swansea-area pharmaceuticals tend to be quality, operations, clinical supply and responsible procurement teams, rather than broad IT or discretionary business-service buyers. Customers are usually B2B healthcare organisations, specialist wholesalers, clinical service providers and public-sector-linked supply chains. Engagements tend to be conservative: supplier qualification, documentation review, batch or account set-up, and continuing compliance checks often matter as much as price. The buyer is usually looking for a licensed, inspected counterparty able to handle regulated medicine flows from South Wales, not a broad life-sciences platform.
Read more
Swansea has 32 actively trading pharmaceuticals companies in this list, making it a small local cohort by UK life-sciences standards. Employment footprint is also modest: current employee disclosures account for 46 staff, indicating that much of the local market operates as small regulated businesses rather than large manufacturing sites. The absence of companies above £5M in reported turnover puts the page closer to a specialist supply-chain and services map than a ranking of large pharmaceutical manufacturers.
UK human medicines sit under MHRA oversight. Organisations making, assembling or importing medicines need a manufacturer’s licence, evidence of good manufacturing practice and regular site inspections; wholesale supply to anyone other than the patient requires a wholesale distribution licence and good distribution practice compliance. Medicines also need marketing authorisation, while NHS access is shaped by cost-effectiveness review through bodies such as NICE. ABPI remains the main trade body for research-based pharmaceutical companies.
Swansea’s cohort appears more likely to evolve through incremental licence extension, niche distribution relationships and service attachment than through a wave of large research campuses. Early-commercial firms tend to face slow qualification cycles, especially where buyers need evidence of inspected premises, validated processes and pharmacovigilance coverage. MHRA and NHS cost-effectiveness requirements keep sales cycles deliberate, so buyer trust and documented quality systems remain barriers to entry. Consolidation may come from wholesalers and specialist service groups seeking compliant local capacity, rather than from generalist healthcare suppliers.
32
Active firms
2026
8
New since 2022
Recent incorporations
0
Above £5M
Revenue threshold
Key facts
25% of the cohort was incorporated since 2022 (8 firms), so a sizeable share is in its first few filing cycles.
The MHRA regulates UK human medicines, including standards, clinical-trial approvals, medicine licensing and pharmacovigilance.
Manufacturers, assemblers and importers of human medicines need an MHRA manufacturer’s licence, good manufacturing practice compliance and regular site inspections.
Wholesale supply to anyone other than the patient requires a wholesale distribution licence and good distribution practice compliance.
£9.0 billion of pharmaceutical R&D was performed by the UK business enterprise sector in 2022, equivalent to 0.36% of UK GDP and 18% of all UK business R&D.
UK pharmaceutical exports were valued at £25.6 billion in 2023, with the UK ranked tenth among comparator countries for this metric.
Top Swansea Pharmaceuticals companies
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsManufactures and supplies unlicensed medicines (“specials”) and special obtain pharmaceutical products. Produces customised formulations for patient‑specific needs and supplies them to healthcare…
Serves NHS and healthcare-sector buyers, including pharmacists and clinicians sourcing patient-specific unlicensed medicines and Special Obtain products.
Financial Health
StableStable · 2% CAGR over 2y
Location
ARCADIA PHARMACEUTICALS LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsManufactures and supplies unlicensed medicines (“specials”) and special obtain pharmaceutical products. Produces customised formulations under Good Manufacturing Practice and distributes medicines to…
Serves NHS and private healthcare organisations, hospital and community pharmacies, and prescribing clinicians seeking unlicensed or special-obtain medicines for individual patient requirements.
Financial Health
StableStable
Location
South Wales Specials Limited
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsManufactures and supplies bespoke pharmaceutical “specials” (unlicensed medicines) for pharmacies, hospitals, dispensing doctors and wholesalers, including oral liquids, suspensions, creams,…
Serves UK pharmacies, dispensing doctors, hospitals and pharmaceutical wholesalers needing bespoke medicinal products, including preparations for paediatric and older patients with swallowing…
Financial Health
DistressedDistressed · -11% CAGR over 5y
Location
Evolve Resources Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides supply chain services for the pharmaceutical sector, including sourcing raw materials, distribution of finished products, logistics, transport and warehousing. Also supports the supply of…
Serves B2B customers in the pharmaceutical, supplements and vitamins sectors, including manufacturers, distributors and supply chain teams managing raw materials, logistics, warehousing and finished…
Financial Health
HealthyHealthy · Hiring · 8% CAGR over 4y
Location
RI Pharma Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed
Location
Kmci Services Ltd
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
HealthyHealthy
Location
SURGERY SUPPLIES (UK) LIMITED
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StableStable
Location
Unlock all 32 leads
Showing 7 of 32 — +25 more with verified decision-maker contacts, live data, and CRM sync.
How Swansea Pharmaceuticals companies work and how to sell to them
What they do
Revenue usually comes from regulated medicine supply rather than IP-heavy drug discovery. Swansea-area pharmaceuticals firms tend to earn through wholesale margins, import and assembly fees, batch handling, documentation work, clinical supply support and recurring account arrangements with healthcare counterparties. Pricing is commonly account-based or per order, with separate charges for qualification packs, validation evidence, storage, release checks or service levels where those are part of the arrangement. The product is often a compliant flow of medicines and evidence: licences, inspected premises, good manufacturing practice or good distribution practice controls, and the paperwork needed for another regulated organisation to accept the goods.
Who they sell to
Customers are usually B2B healthcare organisations, specialist wholesalers, clinical service providers and public-sector-linked supply chains. The practical buyer is often a quality lead, operations manager, clinical supply manager, responsible person, pharmacy lead or procurement team, with finance involved where ongoing account terms or credit exposure matter. Sales cycles are rarely self-serve: most suppliers must pass qualification, provide licence evidence, answer audit questions and maintain approved-supplier status before regular orders follow. Public-sector-linked work is more likely to involve formal procurement, framework access or tender documentation, while private healthcare and wholesale relationships are more often direct and relationship-led.
What they buy
Most Swansea pharmaceuticals firms tend to spend on quality management systems, document control, batch record handling, inventory and order management, audit tracking, pharmacovigilance processes and secure customer portals for exchanging regulated paperwork. They also buy regulatory advice, legal support for contracts and licence matters, accountancy, insurance, recruitment for quality and operations roles, and practical site services linked to inspected premises. Infrastructure spending is usually less about general office software and more about traceability, access control, backed-up records, supplier due diligence and evidence packs that can survive customer audits and MHRA inspection questions.
Why and how to sell to them
Buying intent often appears when a firm applies for, varies or prepares to defend a licence, takes on a new regulated customer, adds import, assembly or wholesale activity, or hires into quality and operations leadership. Newly incorporated businesses can also be receptive if they are building documented processes before their first customer audits. The more credible outbound angle is usually risk and evidence, not generic efficiency: fewer missing records, faster audit responses, clearer ownership of checks, and easier proof that good manufacturing practice or good distribution practice obligations are being followed. Sellers should expect qualification questions and be ready with their own security, continuity and compliance evidence.
How this list is built
Data sources
This list is built from UK Companies House filings, XBRL accounts data, and semantic analysis of each company's public website. Revenue and headcount figures come from the most recent filed accounts; where the company has not filed, values are estimated using a model trained on filed history and peer benchmarks and are labelled as estimates.
Classification
Rather than relying solely on SIC codes, Firmbase classifies each company semantically: the company's website is crawled, an AI model reads what the company actually sells, and the company is placed into the relevant industry and subsectors. SIC codes are used as one signal but not the only one. This means a company that registered under a generic SIC code but pivoted into (for example) fintech is correctly identified as fintech, not as its original SIC category.
Freshness
The underlying company data is refreshed from Companies House continuously; filings appear in the list within days of submission. The curated list ordering is regenerated when the underlying data moves meaningfully (company count changes by more than 5%, a new company enters the top-ranked segment, or the filed-revenue numbers for the top firms change). You can see the last-updated timestamp near the top of the page.
Also in Swansea
Related directories
Frequently asked questions
How many pharmaceuticals companies are there in Swansea?
What counts as a pharmaceuticals company in this list?
Which are the largest pharmaceuticals companies in Swansea?
What do pharmaceuticals companies in Swansea actually do?
How does Swansea pharmaceuticals compare internationally?
How is this list built and how fresh is the data?
How big are the typical pharmaceuticals companies in Swansea?
Are these mostly new or established pharmaceuticals companies?
What SIC codes does this use?
What buying signals should I look for?
Push these 32 companies into your pipeline.
Find the right decision-makers, see verified company data, and export your list in seconds.